Ratings by Piper Sandler (Allison M. Bratzel)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/27/2026 | Ionis Pharmaceuticals | IONS | Maintain | (N/A) |
|
Details | ||
| 2/23/2026 | Ardelyx, Inc | ARDX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2026 | Cogent | COGT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2026 | Travere Therapeutics | TVTX | Maintain | (N/A) |
|
Details | ||
| 2/6/2026 | Ionis Pharmaceuticals | IONS | Maintain | (N/A) |
|
Details | ||
| 2/6/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | (N/A) |
|
Details | ||
| 2/6/2026 | Incyte | INCY | Maintain | (N/A) |
|
Details | ||
| 2/6/2026 | Akebia Therapeutics | AKBA | Maintain | (N/A) |
|
Details | ||
| 2/5/2026 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/26/2026 | IO Biotech | IOBT | Downgrade | Neutral (Overweight) |
0.48 (0.48) |
0% | Details | |
| 1/26/2026 | IO Biotech | IOBT | Downgrade | Neutral (Overweight) |
0.48 (0.30) |
-37.5% | Details | |
| 1/8/2026 | Ardelyx, Inc | ARDX | Upgrade | Overweight (Neutral) |
5.83 (6.19) |
6.17% | Details | |
| 11/19/2025 | IO Biotech | IOBT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2025 | MeiraGTx Holdings plc | MGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2025 | Travere Therapeutics | TVTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2025 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2025 | Incyte | INCY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2025 | Ardelyx, Inc | ARDX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2025 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/22/2025 | IO Biotech | IOBT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/26/2025 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2025 | Ardelyx, Inc | ARDX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/29/2025 | Abivax | ABVX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/23/2025 | Abivax | ABVX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/2/2025 | Abivax | ABVX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/16/2025 | Cogent | COGT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2025 | Inozyme Pharma Inc. | INZY | Downgrade | Neutral (Overweight) |
1.42 (4.00) |
181.69% | Details | |
| 3/26/2025 | Akebia Therapeutics | AKBA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2025 | Akebia Therapeutics | AKBA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2025 | Ardelyx, Inc | ARDX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/12/2025 | MeiraGTx Holdings plc | MGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2025 | Inozyme Pharma Inc. | INZY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2025 | ALX Oncology | ALXO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/7/2025 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2023 | AbCellera Biologics | ABCL | New Coverage | Overweight (N/A) |
4.39 (3.45) |
-21.41% | Details |
